Polaryx Therapeutics activates first site for Phase 2 trial of PLX-200 in rare pediatric disorders
PLYX•Polaryx Therapeutics activated the first site for its SOTERIA Phase 2 trial of PLX-200 at Boys Town National Research Hospital in Nebraska. Five additional US sites are scheduled to open by the end of the first quarter of 2027.
1. First site activated
The first SOTERIA Phase 2 trial site is at Boys Town National Research Hospital in Nebraska and can begin screening eligible participants. The oral treatment will be evaluated for safety and clinical activity in children with four rare lysosomal storage disorders; clinical results have not yet been presented.
2. More sites planned
Five additional US sites are scheduled for activation by the end of the first quarter of 2027, bringing the total to six. Applications submitted in October 2026 seek authorization to conduct SOTERIA in the European Union and United Kingdom in the first quarter of 2027.
